Latest News & Insights
Stay Up to Date with Our Community
Featured
Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis...
Proceeds will fund a global pivotal trial of lead product candidate,...
The SURPASS study is enrolling patients at research sites across the...
ELA026 has demonstrated promising potential as a frontline treatment for patients...
ROC-101 exhibits favorable pharmacokinetics for once-daily dosing
Funding to advance first-in-class pan-ROCK inhibitor through Phase 2a testing in...
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune...
NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2...
Capsida is initiating the Phase 1/2 study for CAP-003, with the...
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance...